Close Menu
Business Voice NowBusiness Voice Now
    Facebook X (Twitter) Instagram
    Business Voice NowBusiness Voice Now
    Subscribe
    • Markets
      • IPO
      • Market News
    • Business
      • FMCG
      • Retail
      • Quick Commerce
      • Startups
    • Healthcare
    • Technology
    • Energy
    • Voices
      • Entrepreneur – CXO Stories
      • Corporate Office story
    • E Magazine
      • Year 2026
        • November 2026
        • October 2026
        • September 2026
        • August 2026
        • July 2026
    Business Voice NowBusiness Voice Now
    Home»Business»Dr. Ajit Kamath, Managing Director Of Arch Pharmalabs Ltd Conferred Honorary Doctorate in Health Administration by Indian Institute of Technical Research and Business Studies
    Business

    Dr. Ajit Kamath, Managing Director Of Arch Pharmalabs Ltd Conferred Honorary Doctorate in Health Administration by Indian Institute of Technical Research and Business Studies

    By February 2, 2022No Comments2 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email
    Follow Us
    Google News Flipboard Threads
    Share
    Facebook Twitter LinkedIn Pinterest Email

    New Delhi (India), February 02: Dr. Ajit Kamath, Promoter and Managing Director of Arch Pharmalabs Ltd, was conferred “Honorary Doctorate in Health Administration by prestigious University The Indian Institute of Technical Research and Business Studies For his exemplary contribution of over 25 years in the field of Pharmaceuticals in a virtual ceremony commemorating  73 Years of the Republic of India.

    Arch Pharmalabs Ltd. is a Mumbai Headquartered company based in India. Arch has multiple USFDA approved facilities with multiple chemistry capabilities from kilogram to multi-ton scale. Arch has been at the forefront of attracting and practising path-breaking technologies in the field of manufacturing of Active Pharmaceutical Ingredients and Intermediates. Arch has been manufacturing, commercially, various import substitutes and complex intermediates covering, but not limited to, blockbuster drugs like Atorvastatin, Rosuvastatin, Ursodeoxycholic Acid etc.

    Recently it has also diversified into Lithium compounds.

    For over two and a half decades, Dr. Ajit Kamath has had extensive top-level decision-making and risk-taking experience in Arch Pharmalabs Limited’s dynamic global business. Accepting the degree, Dr.  Ajit Kamath said, “I am extremely honoured to receive this Honorary Doctorate from a University that plays such an important role in developing the potential and talent of tens of thousands of students from all over the world. May you all be fortunate enough to know someone who will inspire you to feel the joy and satisfaction that comes from helping others.”

    For more information, please visit http://www.archpharmalabs.com/

    Business
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Duroply Showcases its Built-to-Last Legacy

    November 14, 2026

    Austere Systems Announces H1 FY27 Results

    November 14, 2026

    ROX Hi-Tech Announces Unaudited Financial Results for H1 FY27

    November 14, 2026

    Comments are closed.

    Recent Post
    • Duroply Showcases its Built-to-Last Legacy
    • Austere Systems Announces H1 FY27 Results
    • ROX Hi-Tech Announces Unaudited Financial Results for H1 FY27
    • PAN HR Solution Limited Reports H1 FY27 Results
    • Why Colonialism Still Matters: Museum of British Colonialism to Host Online Panel Discussion on 19 November
    • Dr. R. K. Thukral and the Work of Bringing Neuropsychiatry Closer to Patients
    • From Global Recognition to Academic Excellence: LBSIM’s Continuing Journey After AACSB Accreditation
    • DEV Information Technology Reports Q2 FY27 Total Income of Rs. 63.07 Cr, Up 28 Percent YoY; H1 FY27 Total Income Reaches Rs. 107.72 Cr, Up 16 Percent YoY

    Type above and press Enter to search. Press Esc to cancel.